BioMCP by
@imaurer now enables biomedical agents to rapidly explore the treatment landscape for KRAS G12C-positive NSCLC using just seven CLI commands. By integrating data from 10+ biomedical sources, it retrieves therapeutic evidence, maps approved and investigational drugs, reviews FDA safety data, analyzes real-world adverse events, identifies recruiting clinical trials, and summarizes the latest resistance research all within a reproducible, end-to-end command-line workflow.
Explore BioMCP on Asmora today:
Biomedical agents can understand the treatment landscape for KRAS G12C-positive NSCLC by chaining together 7 BIOMCP commands.
The below terminal-based screencast demonstrates the BioMCP commands that:
* Orients across 1,741 known variants and 84 clinical trials
* Pulls CIViC and ClinVar therapeutic evidence for G12C
* Maps 5 drugs targeting KRAS (sotorasib, adagrasib, and 3 investigational)
* Reviews sotorasib's FDA approval history and safety profile
* Checks 2,465 real-world adverse event reports from FDA FAERS
* Finds 62 recruiting trials for KRAS G12C NSCLC
* Retrieves the latest research on resistance mechanisms
7 entity types. 10+ data sources. Under two minutes.
Drugs, evidence, safety, trials, resistance -- the complete picture from a single CLI.
Full walkthrough with every command and output:
Documentation:
GitHub Code repo:
#
BioMCP# #
PrecisionOncology# #
KRASG12C# #
NSCLC# #
AIAgents# #
ClinicalGenomics#
Show more